Categories
Marksans Pharma Limited — Updates, 26-05-2026: Press Release
26-05-2026 · 01:32 pm
Marksans Pharma delivered historic FY26 results: highest-ever Total Income at ₹3,033 Cr, EBITDA ₹601 Cr, and PAT ₹420 Cr. Growth was driven by new product launches and market expansion in US, UK, Australia, Germany, Canada, and Ireland. Net cash positive with ₹990 Cr cash.
No comments yet. Be the first to comment!